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Abstract: Topical application of medical grade honey is recommended for the clinical 
management of wound infections. The suitability of honey as a wound healing agent is largely 
due to its antibacterial activity, immune modulatory properties, and biocompatibility. Despite the 
usefulness of honey in wound healing, chronic wound infections continue to be a global problem 
requiring new and improved therapeutic interventions. Several recent studies have investigated 
the effects of combining honey with other therapies or agents with the aim of finding more 
efficacious treatments. In this systematic review, the database PubMed was used to carry out a 
search of the scientific literature on the combined effects of honey and other therapies on 
antimicrobial activity and wound and skin healing. The search revealed that synergistic or additive 
antimicrobial effects were observed in vitro when honey was combined with antibiotics, 
bacteriophages, antimicrobial peptides, natural agents e.g. ginger or propolis and other treatment 
approaches such as the use of chitosan hydrogel. Outcomes depended on the type of honey, the 
combining agent or treatment and the microbial species or strain. Improved wound healing was 
also observed in vivo in mice when honey was combined with laser therapy or bacteriophage 
therapy. More clinical studies in humans are required to fully understand the effectiveness of 
honey combination therapies for the treatment of skin and wound infections.  
Key words: honey, antibiotics, natural agents, combination therapy, wound infection, skin 
infection. 
Introduction 
Antimicrobial drug resistance is a major public health problem for which novel antimicrobial 
drugs or innovative therapeutic interventions must urgently be found. Globally, incalcitrant 
wounds, caused by antibiotic resistant microbial infections, are a significant burden on health care 
systems 1,2. An increasing global prevalence of diabetes and obesity and an aging population has 
contributed to the current burden of chronic wounds 3,4. Non-healing infected wounds can cause 
sepsis and inflammation in organs e.g. endocarditis leading to increased morbidity and mortality. 
Wounds with biofilms are particularly resistant to treatment with antibiotics because the bacteria 
are protected by a barrier of extracellular polymeric substances 5. Due to the need for new and 
improved therapies there has been a revived interest in alternative treatment approaches such 
as the use of honey in the management of wound infections. Indeed, medical grade honey is 
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currently included in clinical protocols for wound management 6,7 and has been shown to have 
broad spectrum antimicrobial activity against common wound infecting microorganisms including 
Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli 8-10.  Furthermore, 
manuka honey can kill antibiotic resistant bacterial strains such as methicillin resistant 
Staphylococcus aureus (MRSA) and the development of bacterial resistance to honey is thought 
to be unlikely due to its multiple antimicrobial components and mechanisms 11. The wound healing 
ability of honey is also related to its capacity to promote reepithelialisation and angiogenesis and 
stimulate skin and immune cells 12-15. Medical grade honey is defined as organic honey that is 
free of toxic contaminants, has been sterilised by gamma irradiation, is processed in accordance 
with safety regulations and standards and is safe for medical application 16. Medical grade honey 
formulations for the clinical management of wounds include honey in tubes, gels, and 
impregnated dressings. A Cochrane systematic review published in 2015 concluded that there is 
evidence that honey heals partial thickness burn wounds better than conventional treatments and 
post-operative wounds more effectively than gauze or antiseptics 17. For other types of wounds, 
the review stated that there was insufficient evidence to form definitive conclusions. Therefore, 
despite evidence that honey is efficacious for the treatment of certain types of wounds, there is 
still a need to find ways to optimise or enhance its antimicrobial and healing properties for 
improved clinical outcomes. As all honeys are unique, one approach may be to search for honeys 
that have superior antimicrobial activity but are yet undiscovered. Another approach may be to 
modify the honey in such a way that its antimicrobial activity is boosted. Surgihoney, is an example 
of a honey that has been bioengineered so that it produces more hydrogen peroxide and reactive 
oxygen species when diluted in water 18. An alternative approach could involve combining honey 
with other agents such as antibiotics or natural agents such as ginger or propolis with the aim of 
inducing synergistic or additive effects. This systematic review explores the current scientific 
literature on the biological and clinical effects of combining honey with other agents and therapies 
in relation to wound and skin infections. Furthermore, possible mechanisms of the synergistic 
effects of honey combination therapies are described. The overall aim of this article was to 
encourage the development of new and improved treatments for skin and wound infections.  
Review Methods 
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A systematic review investigating the effects of honey combined with other agents or 
therapies on antimicrobial activity and wound and skin infections was conducted in accordance 
with PRISMA guidelines 19. The electronic database PubMed was used for the literature search 
by using key terms shown in Table 1. Group 1 terms were combined with group 2 and 3 terms 
until all the combinations had been searched for. Research articles investigating the combined 
effects of honey and other agents or therapies on antibacterial activity in vitro and on wound and 
skin infections in vivo were included in the study. Other agents included antibiotics commonly 
used for skin and wound infections such as rifampicin, oxacillin and tetracycline and other natural 
products such as propolis, royal jelly, vitamins, and ginger. Examples of other therapies included 
laser therapy, bacteriophage therapy and hydrogel. Articles with full text in English and published 
between 1990 and 2020 were included in the study. Review articles and articles not written in 
English were excluded. Some important articles were also sourced from the reference list of 
included papers and some were recommended by experts in the field. PM and DT carried out the 
literature search including selection and assessment of articles and the search was conducted 
between May and June 2020. Any disagreements during the article assessment process were 
resolved by discussion. We obtained a total of 408 scientific articles and selected 41 studies we 
determined relevant to research on honey combination therapies for wound and skin infections 
(Table 2). 
Table 1. Search terms used in the study 
Term (group 1) Term (group 2) Term (group 3) 
Honey Antibiotic  Wound infection  
 Rifampicin  Skin infection  
 Oxacillin  Wound healing  
 Tetracycline  Antibacterial  
 Combination therapy  Antimicrobial  
 Propolis   
 Herbal extracts  
Combinations: group 1 terms AND group 2 terms AND group 3 terms until all combinations had been 
searched for.  
Table 2. Table created in accordance with PRISMA guidelines showing number of articles 
identified and included in this systematic review 
Search strategy  No. of articles 
Identification Records identified from PubMed database 
searching 
397 
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Records identified from other sourcesͳ 11 
Screening Records after duplicated articles removed 
Records screened by abstract 
Records excluded 
254 
254 
207 
Eligibility Full text articles assessed for eligibility 
Full text articles excluded 
47 
6 
Included Studies included in review 41 
ͳ Other sources included articles sourced from the reference list of selected papers and articles 
recommended by experts in the field.  
Results and Discussion 
Honey and antibiotics: in vitro studies 
Several researchers have explored the effects of combining honey with antibiotics on 
antimicrobial activity in vitro. One of the first papers reporting a synergistic effect of honey and 
antibiotics was published in 1998. The researchers used a broth dilution assay to demonstrate a 
synergistic effect of an Indian honey (obtained from Phondaghat Pharmacy) and the antibiotics 
amikacin, ceftazidine and gentamicin against multi drug resistant clinical isolates of P. aeruginosa 
20. The honey and antibiotics were reportedly tested at a ratio of 1:1. Experiments were also 
conducted with Klebsiella species but no synergy was observed with this micro-organism. Later 
in 2005, another study reported synergy using broth dilution method between an Omani honey 
(50%) and the antibiotic gentamicin (4µg/ml) against Staphylococcus aureus 21. Additionally, a 
study conducted in Egypt reported enhanced effects of antibiotics against clinical isolates of P. 
aeruginosa, Enterobacter species and Staphylococci in a disc diffusion assay when citrus bee 
honey (100%) was added to the antibiotic discs (Oxoid) 22.  
More recently, Jenkins and Cooper (2012) 23 investigated the combined effects of 
subinhibitory concentrations of manuka honey and the antibiotic oxacillin against methicillin 
resistant Staphylococcus aureus (MRSA). In their study, resistance of the MRSA strain to oxacillin 
was confirmed by antibiotic susceptibility testing using Mueller Hinton Agar (MHA) and discs 
coated with 5µg of oxacillin. No zones of inhibition were observed confirming that the S. aureus 
strain was methicillin resistant. However, when a sub-inhibitory concentration of manuka honey 
(5% w/v) was added to the MHA, inhibition zones of 32 mm in diameter developed around the 
oxacillin discs. The findings suggest that the subinhibitory concentration of manuka honey 
affected the bacteria in such a way that resistance to oxacillin was reversed. Using broth dilution, 
chequerboards and time kill curves Jenkins and Cooper (2012) confirmed the synergistic 
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interaction of manuka honey and oxacillin, and reversal of oxacillin resistance. β lactam antibiotics 
such as oxacillin, methicillin and cefoxitin inhibit bacterial cell wall synthesis by binding to bacterial 
penicillin binding protein (PBP), a protein involved in the synthesis of the peptidoglycan layer of 
the bacterial cell wall. In methicillin resistant strains of S. aureus an altered PBP protein with a 
low binding affinity for β lactam antibiotics is produced. This altered form of PBP is known as 
PBP-2a and is encoded by the mecA gene and regulated by a sensor inducer called mecR1. 
Expression of mecA and subsequent production of PBP2a enables bacteria to survive in the 
presence of the β lactam antibiotics. Jenkins and Cooper (2012) demonstrated using microarray 
technology that manuka honey (10% w/v) down regulated mecR1 gene product in MRSA.  
However, synergistic effects of oxacillin and manuka honey have also been observed in methicillin 
sensitive strains of S. aureus that do not have the mecA gene suggesting that other mechanisms 
are likely to be involved 24, 25. Jenkins and Cooper (2012) 26 went on to investigate antimicrobial 
activity of 15 antibiotics in combination with subinhibitory concentrations of manuka honey 
(Manukacare 18+, Comvita, 5% w/v) against MRSA and P. aeruginosa. The results depended on 
the antibiotic, the bacterial species, and experimental method used. Most notable were the results 
of the combination of tetracycline and manuka honey which demonstrated enhanced activity 
against MRSA and P. aeruginosa. Rifampicin and manuka honey showed enhanced effects 
against MRSA when tested using disc diffusion and E-strip but synergy was not observed using 
broth dilution. The combination of imipenem and manuka honey was found to be synergistic 
against MRSA but not P. aeruginosa suggesting a species-specific effect. Subsequently, Muller 
et al, (2013) 25 reported synergistic effects of manuka honey and rifampicin against several S. 
aureus isolates including MRSA. The experimental methods used were checkerboard, 
microdilution assays and agar disc diffusion assay. In the agar disc diffusion assay, for example, 
the addition of 5% Medihoney (Comvita Ltd, NZ) to the agar increased the zone of inhibition 
induced by rifampicin (4µg discs) from 20 mm to 41 mm. A similar result was obtained for a range 
of S. aureus isolates, however, no zones of inhibition were observed around a rifampicin resistant 
strain of S. aureus either with or without 5% Medihoney in the agar suggesting that Medihoney 
could not reverse rifampicin resistance. Nevertheless, experimental results suggested that 
Medihoney could prevent the emergence of resistance as resistant colonies were observed on 
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agar plates with rifampicin and 5% sugar solution but not on rifampicin and 5% Medihoney plates. 
Rifampicin is an effective drug for the treatment of S. aureus wound and skin infections, but 
resistance can emerge readily. Resistance is due to a single point mutation in the rpoB gene that 
encodes the β subunit of RNA polymerase, the target of rifampicin. The authors suggested that 
Medihoney could prevent occurrence of the mutations that cause resistance or Medihoney and 
rifampicin combination did not allow the bacteria to survive long enough to develop resistance. 
The researchers also investigated the effects of methylglyoxal (MGO), the main antimicrobial 
component of manuka honey, in combination with rifampicin on antibacterial activity and 
concluded that MGO (70 µg/mL) exerted an additive rather than a synergistic effect. The authors 
were of the view that MGO was not fully responsible for the synergistic antibacterial effects of 
manuka honey and suggested that other compounds in the honey such as polyphenols may be 
involved. Similarly, Hayes et al., (2018) 27 reported that manuka honey or MGO enhanced the 
activity of the antibiotic linezolid against both a methicillin sensitive and a methicillin resistant 
strain of S. aureus. MHA plates that contained 5% manuka honey (Manuka Health, Auckland, NZ) 
or MGO (27.5µg/mL) compared to control plates containing a 5% sugar solution caused a 
statistically significant increase in linezolid (30µg) induced zones of inhibition. In contrast, an 
unpasteurised honey did not enhance the activity of linezolid. Checkerboard microdilution assays 
determined that in this study the effects of MGO were synergistic rather than additive. Linezolid 
is effective against many Gram-positive bacteria including S. aureus and acts by inhibiting 
bacterial protein synthesis. The researchers went on to show that MGO increased the intracellular 
accumulation of linezolid in bacterial cells. In support of a role for MGO, preliminary experiments 
conducted by Raimkulov (2019) 28 demonstrated that 5% manuka honey (Comvita Medihoney® 
Wound gel) or MGO (27.5µg/mL) in tryptone soya agar (TSA) plates enhanced the zone of 
inhibition induced by rifampicin discs against a clinical isolate of MRSA in comparison to TSA 
plates containing an artificial honey solution. In the same experiments, Activon medical grade 
manuka honey (Advancis Medical, UK) and two Kazakhstan honeys (buckwheat and buckwheat 
& multifloral) did not enhance the activity of rifampicin against MRSA 28. Similarly, 8 local honeys 
from the Muscat area of Oman, did not enhance the antimicrobial activity of amoxicillin (10 µg) or 
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clarithromycin (15 µg) when 50 µl of 100% honey and antibiotics were placed on Helicobacter 
pylori inoculated agar plates at various distances apart 29.   
Synergistic effects of sub-inhibitory concentrations (< 8% w/v) of manuka honey (Comvita, 
Ltd) and rifampicin on S. aureus biofilm formation and on established biofilms have also been 
observed in vitro 24, 30. Interestingly, some antibiotic combinations (clindamycin, gentamicin and 
oxacillin) showed an antagonistic effect on S. aureus established biofilms when the honey was 
used at sub-inhibitory concentrations but not at higher honey concentrations above the MIC (e.g. 
16% w/v). Physiological and metabolic differences in bacteria within a biofilm could impair the 
ability of sub-inhibitory concentrations of honey in combination with antibiotics to kill the bacteria. 
Other researchers support the occurrence of enhanced effects of honey and antibiotics. 
Klein et al, (2020) 31, used a broth culture assay to investigate the ability of subinhibitory 
concentrations of a range of medical grade honeys (Comvita® Manuka Medihoney®; Comvita® 
Medihoney® Antibacterial Wound Gel™; Revamil® gel; and Surgihoney™RO®) to enhance the 
activity of antibiotics (tetracycline, sulphatriad, streptomycin, penicillin G, chloramphenicol and 
ampicillin) against S. aureus and P. aeruginosa. In their study, bacteria were incubated aerobically 
overnight in broth cultures containing 10% honey. Samples from these cultures were then spread 
onto TSA plates and antibiotic discs (Mastring-S, Mast Group Ltd) were added to the agar and 
incubated at 37oC. The researchers found that the ability of the honeys to enhance the activity of 
the antibiotic depended on the type of honey, the antibiotic, and the bacterial species. Their key 
findings were that Surgihoney™RO® and Comvita® Medihoney® Antibacterial Wound Gel™ 
increased the activity of tetracycline and ampicillin against S. aureus and increased the activity of 
tetracycline against P. aeruginosa.  
There is sufficient evidence to suggest that honey can function synergistically with 
antibiotics to increase bacterial killing in vitro. The outcome however is influenced by the 
concentration and the type of honey, the bacterial species or strain, the status of the bacteria i.e. 
planktonic versus biofilm and the type of antibiotic. Processes are not fully understood but 
possible mechanisms are suggested in Figure 1. Honey is known to contain a complex mixture 
of polyphenols each of which could act individually or synergistically with other polyphenols or 
other antimicrobial components to exert diverse biological effects. Furthermore, antibiotic groups 
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kill bacteria via different mechanisms and therefore the interaction of antibiotics with the unique 
components in different types of honey would likely result in diverse outcomes. Polyphenols may 
be important in the synergistic interactions of honey and antibiotics, but their role requires further 
investigation. Table 3 summarises key research findings on the antimicrobial effects in vitro of 
honey and antibiotic combinations. 
 
Figure 1. Possible mechanisms by which honey and antibiotics synergistically kill bacterial cells
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Table 3. Summary of the key in vitro findings of the antimicrobial activity of honey and antibiotic combinations  
Type of honey Antibiotic Method Micro-
organism 
Key findings Reference 
Manuka honey 
(5% w/v) 
Oxacillin Disc diffusion, 
E-test strip, 
broth dilution, 
chequerboards, 
growth curves. 
MRSA Synergistic antimicrobial activity against MRSA and reversal of 
oxacillin resistance. 
23 
 
 
 
Manuka honey 
(Manukacare, 
18+, Comvita), 
(5% w/v) 
15 antibiotics Disc diffusion, 
E-test strip, 
broth dilution, 
chequerboards, 
growth curves. 
MRSA 
P. aeruginosa 
Synergistic antimicrobial activity against MRSA for manuka 
honey and tetracycline, imipenem and mupirocin combinations 
and additive activity against P. aeruginosa for manuka honey 
and tetracycline, rifampicin and colistin combinations. 
 
 
26 
Medihoney 
(Comvita Ltd) 
5%, 7% w/v 
Rifampicin 
 
Disc diffusion 
assay, 
chequerboards, 
time kill curves. 
MRSA, clinical 
isolates of S. 
aureus. 
Synergistic antimicrobial activity of Medihoney and rifampicin 
combination against MRSA and clinical isolates of S. aureus. 
 
25 
Manuka honey 
(Comvita Ltd) 
(<8%) 
Rifampicin, 
oxacillin, 
gentamicin, 
clindamycin 
 
 
 
Disc diffusion 
assay, 
chequerboards 
Strains of S. 
aureus 
(planktonic 
growth and 
biofilm 
formation) 
Rifampicin and manuka honey considered to be most effective 
as demonstrated synergistic antimicrobial activity against all 
tested strains including planktonic bacteria and S. aureus biofilm 
formation. 
Clindamycin or oxacillin manuka honey combinations 
demonstrated synergistic antimicrobial activity against most 
strains (planktonic and biofilm formation) but not all.  
Gentamicin and manuka honey combinations demonstrated an 
additive antimicrobial effect. 
 
 
24 
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Manuka honey 
(Medihoney, 
Comvita Ltd) 
(inhibitory and 
subinhibitory 
concentrations 
tested).  
Rifampicin, fusidic 
acid, 
clindamycin, 
gentamicin, 
oxacillin. 
Checkerboard 
microdilution 
assays, viability 
assays, 
MacSynergy II 
analysis. 
 
 
S. aureus, 
established 
biofilm 
Most effective combination against established S. aureus 
biofilms was rifampicin and Medihoney. Fusidic acid and 
Medihoney combination induced some synergistic antimicrobial 
effects. 
Clindamycin, gentamicin, and oxacillin Medihoney combinations 
induced antagonistic effects against S. aureus established 
biofilms when honey was used at sub-inhibitory concentrations 
but not at inhibitory concentrations.  
 
30 
Manuka honey 
(Manuka Health, 
NZ) (5%) 
 
Linezolid Disc diffusion 
assay 
MRSA and 
MSSA strains of 
S. aureus 
Manuka honey increases the sensitivity of MRSA and MSSA to 
linezolid. 
27 
Four medical 
grade honeys: 1. 
Comvita® 
Manuka 
Medihoney® 
2. Comvita® 
Medihoney® 
Antibacterial 
Wound Gel™;  
3. Revamil® gel  
4.Surgihoney™
RO® 
 
Tetracycline, 
sulphatriad, 
streptomycin, 
penicillin G, 
chloramphenicol 
and ampicillin. 
Broth culture 
assay 
S. aureus 
P. aeruginosa 
Surgihoney™RO® and Comvita® Medihoney® Antibacterial 
Wound Gel™ increased the sensitivity of S. aureus to 
tetracycline and ampicillin.  
Comvita® Manuka Medihoney® did not enhance the sensitivity 
of S. aureus to any of the antibiotics tested. 
Comvita® Medihoney® Antibacterial Wound Gel™, Comvita® 
Manuka Medihoney® and Surgihoney™RO® enhanced the 
sensitivity of P. aeruginosa to tetracycline. 
Whether the enhanced antimicrobial effects were synergistic, or 
additive was not determined in this study.  
41 
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Honey and antibiotics: in vivo studies 
Studies specifically investigating synergistic effects of honey and antibiotic combinations in 
vivo are lacking. One study by Mat Lazim et al, (2012) 32 involved the use of tualang honey and 
the antibiotic sultamicillin for the treatment of wounds occurring after tonsillectomy. An open 
labelled prospective randomised clinical trial involving two treatment groups was conducted. In 
the first group, 35 tonsillectomy patients (average age of 9) received intra-operative oral 
administration of 3 mls of tualang honey and then post-operative oral administration of 4 mls of 
tualang honey 3 times daily for seven days. In addition to the honey treatment, group 1 also 
received intravenous 25mg/kg sultamicillin three times daily for 2 days and then oral sultamicillin 
two times daily for 5 days. In group 2, 28 tonsillectomy patients (average age 11) were treated 
with the antibiotic regime only. The authors reported that wound healing was significantly faster 
in the honey and antibiotic treated group in comparison to the antibiotic only treated group. Case 
reports also exist, for example, one report of a diabetic patient with a chronic ulcer on the right 
lower limb described successful healing following treatment with honey dressings, systemic 
antibiotic therapy, surgical toilet, and skin graft 33. Similarly, another case study reported on the 
successful healing of a deep diabetic foot ulcer in a 38 year old female patient treated with 
intravenous antibiotics (metronidazole  and ceftriaxone), surgical debridement and daily dressings 
covered with trigona honey (harvested from the Borneo jungle) 34.  
Clearly more research that specifically investigates the combined effects of honey and 
antibiotics in vivo is required to fully determine clinical effectiveness. It is also important to 
consider how honey and antibiotics should be administered clinically to maximise synergistic or 
additive effects. In wound management, an antibiotic may be administered systemically facilitating 
entry from the base of the wound, whilst honey is administered topically, reaching the upper 
surface of the wound. In diabetic patients, the ability of systemically administered antibiotics to 
reach the wound may be impaired due to poor circulation. An alternative approach may be to 
administer both the honey and the antibiotic topically. Another factor to consider is the 
concentration of honey to use. In wound healing, high concentrations of honey (>90% w/v) are 
commonly used, yet many of the experiments investigating synergistic effects of honey and 
antibiotics in vitro have used low subinhibitory concentrations of honey e.g. 5% w/v. Furthermore, 
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despite the general believe that bacterial resistance to honey does not occur there is one study 
that suggests that resistance is possible. Camplin and Maddocks (2014) demonstrated that P. 
aeruginosa biofilms treated with manuka honey (Medihoney, Comvita) developed increased 
resistance to manuka honey and to the antibiotic’s imipenem and rifampicin, as demonstrated by 
an increase in minimal inhibitory concentration (MIC) in recovered isolates 35. The resistance was 
suggested to be due to small colony variants and the authors suggested that in clinical practice 
medical honey should be administered for a sufficient period of time and in combination with other 
antimicrobials so that the infection is sufficiently cleared and the chances of resistance reduced. 
In vivo clinical studies are needed to fully understand the combined effects of honey and 
antibiotics in wound management and to determine treatment protocols that optimise synergistic 
or additive interactions and healing.  
Honey and other natural agents: in vitro studies 
In vitro research has also examined the antimicrobial effects of combining honey and other 
natural agents such as ginger, royal jelly, propolis and vitamins. Ewnetu et al, (2014) 36 reported 
that mixtures of Ethiopian honey and ginger extracts (50% v/v) had superior antimicrobial activity 
than ginger extract (50% v/v) or honey alone (50% v/v) in a well diffusion assay against E. coli, 
Staphylococcus aureus (MRSA), and antibiotic resistant strains of E. coli and K. pneumoniae. 
Reportedly, the honey and ginger extract combination induced larger zones of inhibition than 
standard antibiotic discs. Boukraa (2008) 37 described enhanced effects of subinhibitory 
concentrations of Algerian honeys (orange blossom and eucalyptus) when combined with royal 
jelly against P. aeruginosa. For example, when compared with the MIC of honey alone there was 
a considerable decrease (~ 90%) in the MIC when honey (1% v/v) was combined with 3% royal 
jelly. Al-Waili et al, (2012) 38 using broth macro-dilution reported synergistic effects of subinhibitory 
concentrations of sumra honey from Saudi Arabia when combined with subinhibitory 
concentrations of propolis against S. aureus, E. coli C. albicans and mixed microbial cultures. The 
MICs of honey and propolis combinations were lower than honey and propolis alone against all 
micro-organisms tested in the study. Propolis obtained from Saudi Arabia demonstrated superior 
synergistic effects in comparison to propolis obtained from Egypt suggesting that the type of 
propolis is important. In a short communication by Kowalski and Makarewicz (2017) 39 honey 
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supplemented with 1% propolis demonstrated higher antibacterial activity than honey alone 
against E. coli in a well diffusion assay. Similarly, Oses et al, (2016) 40 reported synergistic 
antimicrobial effects of honeys from Spain against E. coli, S. aureus and P. aeruginosa in a disc 
diffusion assay when ethanol extracts of propolis (0.1, 0.3 or 0.5%) were added to the undiluted 
honey. Furthermore, the anti-inflammatory effects of the honey (75%), measured using a 
hyaluronidase inhibition assay, were enhanced when propolis ethanol extracts were added. 
Honey has also been combined with other natural agents including cinnamaldehyde found in 
cinnamon and carvacrol, a monoterpene found in thyme. The combination of honey obtained from 
Damavand district Iran, with sub-MIC concentrations of cinnamaldehyde and carvacrol had 
greater antibacterial activity than honey alone against suspensions of clinical isolates of P. 
aeruginosa 41. This triple combination was also reported to reduce the expression of exoS gene 
involved in P. aeruginosa virulence and ampC gene involved in P. aeruginosa resistance to 
antibiotics such as carbapenems and monobactams. Even more complex mixtures of natural 
agents have been tested. For example, Dashtdar et al, 2016 42 prepared a gel composed of herbal 
extracts of Acacia catechu, Castanea sativa, Ephedra sinica and Momia combined with honey 
(25%), maple saps, Phoenix dactylifera (date), pomegranate extract and Azadirachta indica gum. 
This gel had a higher antibacterial activity in an agar well diffusion assay than the antibiotic 
cloxacillin or honey alone against P. aeruginosa. Natural bioactive agents such as vitamins have 
also been combined with honey and antimicrobial activity assessed. Majtan et al, (2020) 43 
investigated the antimicrobial activity of Slovakian honeys and a commercially available UMF 15+ 
manuka honey (Natures Nectar, UK) supplemented with sub-MIC concentrations of vitamin C in 
an MIC assay against bacterial isolates including  P. aeruginosa and S. aureus  as well as against 
P. aeruginosa, S. aureus, S. agalactiae and E. faecalis multi-species biofilms. Their key findings 
were that supplementation of honey with sub-MIC concentrations of vitamin C reduced the MIC 
of all types of honey against planktonic preparations of P. aeruginosa. In contrast, 
supplementation of honeydew honey with sub-MIC concentrations of vitamin C increased the MIC 
against planktonic S. aureus. Honeydew honey (100%) supplemented with vitamin C (100mg/g 
of honey) had superior antibiofilm activity than honey alone and caused clearance of all the 
bacterial species within the biofilm after 48 hours. Vitamin C is reported to have antibacterial 
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activity and the authors suggested that the antibacterial effects of honey and vitamin C 
combination may be due to increased production of reactive oxygen species in bacterial cells. In 
another study, L-Mesitran, a medical honey formulation containing 40% Mexican yucatan honey 
and vitamins C and E was reported to have anti-fungal activity against Candida albicans whilst 
40% Mexican yucatan honey alone did not 44.  The authors suggested that the vitamins or other 
components in the L-Mesitran formulation may be enhancing the antifungal activity of the honey. 
Furthermore, L-Mesitran formulation was found to have superior antimicrobial activity against 
Staphylococcus pseudintermedius, a cause of canine pyoderma, and Malassezia pachydermatis 
in comparison to the honey component of L-Mesitran only 45. The authors again concluded that 
other components in the L-Mesitran formulation which include medical grade hypoallergenic 
lanolin, propylene glycol, polyethylene glycol 4000 and vitamins C and E may be enhancing the 
antimicrobial activity of the honey.  
Synergism between honey and other natural agents could be due to interactions between 
constituent polyphenols or both substances may be acting on similar mechanistic pathways 
leading to an enhanced biological effect. Table 4 summarises key research findings on the 
antimicrobial effects in vitro of honey and natural agent combinations. 
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Table 4. Summary of the key in vitro findings of the antimicrobial activity of honey and natural agent combinations  
Type of honey Natural agent Method Micro-organism Key findings Reference 
Ethiopian honey 
(50% v/v) 
Ginger extracts 
(50% v/v) 
Prepared honey 
ginger mixture 
(50% v/v). 
Agar well 
diffusion assay, 
broth assay. 
S. aureus, MRSA, 
E. coli (sensitive 
and resistant 
strains). K. 
pneumoniae 
(resistant) 
Honey and ginger combination induced higher mean 
zones of inhibition than honey or ginger alone or 
standard antibiotic discs (methicillin, penicillin, 
amoxacillin). MBC of honey-ginger extract was 12.5% 
for all bacteria tested.  
36 
 
 
 
Algerian honey 
(orange 
blossom, 
eucalyptus) 
Royal jelly (sub- 
MIC 
concentrations 
(3% (v/v); 2% 
(v/v); 1% (v/v) 
added to honey). 
MIC assay P. aeruginosa For each type of honey there was > 90% decrease in 
the MIC when 3% (v/v) royal jelly was added; a 66.6% 
decrease in MIC when 2% (v/v) royal jelly was added 
and a 50% decrease in MIC when 1% (v/v) royal jelly 
was added. 
 
 
37 
Saudi Arabian 
sumra honey 
(Acacia tortilis)  
Ethyl alcohol 
extract of propolis 
(Egyptian and 
Saudi Arabian) 
(sub MIC 
concentrations) 
 
MIC assay S. aureus, E. coli, 
C. albicans, 
polymicrobial 
cultures. 
The MIC of mixtures of honey and propolis combined 
were lower than honey or propolis alone.  
 
38 
Polish honey 
(lime) 
(75% w/w) 
Ethanol extract of 
propolis (1%), 
 
 
 
Agar well 
diffusion assay 
E. coli Larger zones of inhibition when honey was enriched 
with 1% propolis.  
 
 
39 
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Spanish honeys 
(heather, 
chestnut and 
multifloral) 
Ethanol extracts 
of propolis (0.1, 
0.3 or 0.5%) 
harvested from 
Spain. 
Agar diffusion 
assay 
Microorganisms 
including E. coli, S. 
aureus, P. 
aeruginosa. 
In general, enhanced antimicrobial activity was 
observed when honey was supplemented with propolis. 
The increase varied depending on the type of honey, 
concentration of propolis and test micro-organism. 
40 
Iranian honey 
from Damavand 
district, Iran. 
Cinnamaldehyde 
and carvacrol 
(sub-MIC 
concentrations) 
Broth dilution 
method 
P. aeruginosa The MIC of the combination of honey, cinnamaldehyde 
and carvacrol was considerably lower than honey alone 
(0.49µg/mL vs 114.2 μg/mL respectively). The 
antibacterial activity of the triple combination was 
reportedly greater than imipenem. 
 
 
 
41 
Iranian honey 
(25%) from 
Fasa, Iran 
Gel composed of 
herbal extracts of 
Acacia catechu, 
Castanea sativa, 
Ephedra sinica 
and Momia 
combined with 
honey (25%), 
maple saps, 
Phoenix 
dactylifera (date), 
pomegranate 
extract and 
Azadirachta 
indica gum 
Agar well 
diffusion assay 
P. aeruginosa  Zone of inhibition induced by the herbal gel formulation 
was greater than honey alone (35.1 mm vs 13.1 mm 
respectively).  
42 
Slovakian 
honeys 
(sunflower, 
Vitamin C 
(Sub-inhibitory 
concentrations) 
MIC assay 
 
 
Planktonic bacteria 
including P. 
Supplementation of honey with vitamin C reduced the 
MIC of all honey types tested against planktonic P. 
aeruginosa. Supplementation of honeydew honey with 
43 
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acacia and  
honeydew) 
UMF 15+ 
manuka honey 
(Natures Nectar, 
UK) 
 
 
 
Biofilm wound 
model 
 
 
aeruginosa and S. 
aureus. 
 
Multispecies 
biofilms (P. 
aeruginosa, S. 
aureus, S. 
agalactiae, E. 
faecalis) 
 
vitamin C increased the MIC against planktonic S. 
aureus.  
 
Honeydew honey supplemented with Vitamin C 
(100mg/g) had superior antibiofilm activity than honey 
alone.  
 
 
Mexican 
yucatan honey 
(L-Mesitran) 
 
 
Vitamins C and E 
L-Mesitran 
contains 40% 
Mexican yucatan 
honey and 
vitamins C and E 
Antifungal MIC 
method for 
yeasts 
 
C. albicans L-Mesitran demonstrated antifungal activity against C. 
albicans (MIC 25%–50%), whereas 40% Mexican 
yucatan honey did not.  
 
 
44 
Mexican 
yucatan honey 
(L-Mesitran) 
Vitamins C and E 
L-Mesitran 
contains 40% 
Mexican yucatan 
honey and 
vitamins C and E 
Microbroth 
assay to 
determine MBC 
Staphylococcus 
pseudintermedius, 
Malassezia 
pachydermatis 
L-Mesitran had lower MBC in comparison to the honey 
component of L-Mesitran only. 
 
 
45 
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Honey and other natural agents: in vivo studies 
Again, few studies have specifically investigated the therapeutic effects of honey combined 
with other natural agents in vivo. One case report by Lofty et al, (2006) 46 described the case of a 65-
year-old diabetic male patient with a deep infected wound on the foot. The patient was treated with 
systemic antibiotics; metronidazole (1500 mg per day) and combined amoxicillin with clavulanic acid 
(1500 mg/day) for 10 days. Thereafter, ciprofloxacin (1500 mg/ day) was used. Healing of the wound 
reportedly improved significantly when the wound was treated topically every day with a paste 
containing 800 mg of bee propolis and 50 g of myrrh mixed with honey. In a prospective, open-label 
block randomised controlled clinical study conducted in horses it was found that intralesional 
application of L-Mesitran to wounds prior to wound closure improved healing and reduced infection 
(data from 69 horses) in comparison to wounds that were not treated with L-Mesitran (data from 58 
horses)  47.  Furthermore, Nair et al (2020) reported on the successful healing of diabetic foot ulcers 
(six patients) following topical application of L-Mesitran 48. The wounds had previously failed to 
respond to a range of other treatments including antibiotics. Another case study reported on 
successful eradication of infection in an MRSA infected titanium mesh in an incisional hernia in a 70-
year-old female patient treated with L-Mesitran 49. The honey formulation was applied to the wound 
cavity and covered with gauze daily.  More studies conducted in humans are needed to fully 
determine the efficacy of the combination of honey and other natural agents for the treatment of skin 
and wound infections.  
Honey and other therapies (in vitro and in vivo studies) 
Other therapeutic agents being considered for use in combination with honey for the treatment 
of wounds include honey and bacteriophage therapy, honey supplemented with antimicrobial 
peptides, honey combined with cyclodextrins or hydrogel or honey and laser therapy. Novel 
approaches to wound healing have involved adding a combination of antimicrobial agents to 
nanofibrous scaffolds. For example, Sarhan and Azzazy (2017) 50 reported that honey (Egyptian 
clover) (30%) chitosan nanofibers loaded with bee venom (0.01%) and bacteriophages had superior 
antimicrobial activity in a broth culture assay against MDR P. aeruginosa in comparison to ionic silver 
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containing Aquacel-Ag wound dressing. Furthermore, the novel honey bacteriophage dressing 
demonstrated better wound healing ability in mice when compared to Aquacel-Ag wound dressing.  
Oliveira et al, (2017) 51 also reported synergistic antimicrobial effects against E. coli biofilms formed 
on 96 well plates at 12 and 24 hours using multi-floral Portuguese honey and an E. coli specific 
bacteriophage. This approach combines the antibiofilm effects of honey with the ability of 
bacteriophages to lyse bacteria. Scanning electron microscopy revealed that honey caused 
perturbations in the membrane of the E. coli whilst the bacteriophage caused complete lysis with only 
vesicle structures left behind.  
Kwakman et al, (2011) 52 investigated the antimicrobial effects of supplementing Revamil honey 
with the antimicrobial peptides LL-37 and the synthetic peptide bacterial peptide 2 (BP2). They 
reported that the antimicrobial activity of LL-37 was inhibited in the presence of honey, but this was 
not the case for BP2. Using a liquid bactericidal assay, it was shown that Revamil honey 
supplemented with 75µM BP2 had more rapid antibacterial activity against MRSA and extended 
spectrum β lactamase (ESBL) E. coli and had a broader spectrum of antibacterial activity than 
Revamil alone. The authors considered supplementing the honey with hydrogen peroxide or MGO 
but were concerned that high levels of these components may not be biocompatible. 
Hydrogel is commonly used as a wound dressing. It is composed of polymers suspended in 
water and is thought to provide hydration to a wound and promote healing. El-Kased et al, (2017) 53 
reported that an Egyptian honey (75%) chitosan hydrogel formula had superior antimicrobial activity 
against P. aeruginosa, S. aureus, K. pneumonia and Streptococcus pyogenes in a disc diffusion 
assay in comparison to pure honey. For example, the mean zone of inhibition for the honey 75% 
chitosan hydrogel formula against S. aureus was 20.2 ± 0.4 vs 15.1 ± 0.9 for pure honey. This formula 
was also superior to pure honey in the healing of 10 mm burn wounds induced in mice using a heated 
metallic rod. The wounds were treated with either the honey 75% chitosan hydrogel formula or pure 
honey for 9 days. By day 9, the honey chitosan treated wounds had a mean diameter of 3.8 ± 0.2 
versus 5.3 ± 0.8 in the honey only treated group. Furthermore, an alginate-based honey hydrogel 
containing thymol-based honey from Damavand, Iran was reported to have superior wound healing 
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ability in rats with infected burn wounds than honey alone 54. Wound healing was faster in the alginate 
based honey hydrogel treated group in comparison to the honey only group.  In another study, a 
paste composed of carboxymethyl cellulose hydrogel (50%), water (30%) and chestnut honey (20%) 
had superior antimicrobial activity against S. aureus and E.coli in a disc diffusion assay than a paste 
composed of carboxymethyl cellulose hydrogel (50%) and water only 55. Furthermore, the paste 
containing 20% chestnut honey had superior wound healing ability in comparison to the paste without 
honey in the treatment of wounds inflicted in the dorsal skin of mice. Tavaloki and Tang (2017)56  
designed a wound dressing consisting of a high concentration of honey, polyvinyl alcohol hybrid 
hydrogel and borax as a crosslinking agent. High concentrations of honey are important for wound 
healing but can negatively affect the physiochemical properties of hybrid hydrogels. The use of borax 
apparently overcomes this problem and permits the incorporation of high concentrations of honey 
without negative effects. 
Alpha-cyclodextrin is an oligosaccharide that has also been complexed with manuka honey in 
a formulation named Manuka honey with CyclopowerTM and supplied by Manuka Health New Zealand 
Ltd. Using MIC, MBC and time course experiments Manuka honey with CyclopowerTM was found to 
have improved bacteriostatic activity against S. aureus, MRSA and P. aeruginosa in comparison to 
uncomplexed manuka honey also supplied by the same company 57.  
Researchers have also explored the use of honey combined with laser treatment for wound 
healing. Yadav et al, (2018) 58 investigated the combined effect of medical grade manuka honey 
(Medihoney, Derma Sciences Inc.) and 904 nm super pulsed laser treatment on the healing of full 
thickness burn wounds induced in rats. The wound healing effects of pulsed laser therapy in the red 
and near infrared spectrum is not fully understood, but it has been suggested that photon energy from 
this wavelength is absorbed by chromophores in the skin leading to modulation of transcription 
factors, changes in protein synthesis and enhanced cell proliferation and survival. Combining the 
antimicrobial effects of honey with the wound healing effects of laser therapy is a unique and novel 
approach to wound healing. In their study, 4 groups of 6 rats were used. In group 1, wounds were 
treated with super pulsed 904nm laser treatment, 0.2 J/cm2 daily for seven consecutive days post 
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wound. Group 2 wounds were treated with honey (applied topically over the surface of the wound, 1-
hour post burn wound, and daily for 7 consecutive days post wound). Group 3 wounds were treated 
with a combination of the super pulsed 904nm laser treatment regime and the honey regime, whilst 
group 4 wounds were left untreated. The findings demonstrated that the group that received the 
combination therapy had enhanced wound closure, as measured using image J software, and 
evidence of lower levels of inflammation indicated by lower levels of TNF-α, IL-1β and COX-2 protein 
expression in the wound tissue in comparison to the other groups.  
Rudzka-Nowak et al, (2010) 59 reported on the case of a 55-year-old woman with inflamed and 
necrotic lesions in the abdominal integuments and lumber region following rupture of the colon. The 
wound was infected with E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii. The patient was 
treated with antibiotics linezolidum and metronidazole and then with manuka honey activon tulle 
dressings (replaced on alternate days) as well as the Genadyne A4 negative pressure wound therapy 
system. Genadyne A4 provides sub atmospheric pressure across a wound and is reported to reduce 
swelling, remove wound exudate and bacteria from the wound surface, and stimulate growth of 
fibroblasts and endothelial cells. Following 3 weeks of the combined treatment the wound healed 
sufficiently enough for a skin graft to be performed.  
 
Conclusions 
There are several therapeutic agents or therapies that could potentially be combined with 
honey to enhance antimicrobial activity and wound and skin healing. In vitro studies have investigated 
the combination of honey with antibiotics, natural agents e.g. propolis, bacteriophages, antimicrobial 
peptides, laser treatment and hydrogel. The available research suggests that several honey 
combination therapies have superior antimicrobial activity in comparison to honey alone and in some 
cases, the effect is synergistic. Honey could be supplemented with other agents as a formulation or 
as an additional therapy. Honey contains a range of antimicrobial components, including sugar, 
hydrogen peroxide (H2O2), MGO, polyphenols and antimicrobial peptides. Consideration could be 
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given to supplementing honey with either of these components. However, the combining agent as 
well as being able to increase antimicrobial activity should be biocompatible and promote re-
epithelialisation and wound closure. Therefore, consideration should be given to the potential toxicity 
of the combining agent as well as the most effective honey to use. Whilst manuka honey has been 
shown to promote reepithelialisation certain honeys may be more cytotoxic to skin cells than others. 
Modern delivery methods such as biomimetic nanostructured meshes developed using a layer by 
layer assembly method allow for a more controlled release of honey that may have lower cytotoxicity 
and could be more appropriate for the treatment of certain types of wounds or skin lesions 60. Modern 
bioengineering methods have also involved incorporating honey into cryogels 61. The pH of the 
combining agents used should also be considered as low acidic pH is thought to be more favourable 
for wound healing (personal communication, Dr Lorna Fyfe) and attention could also be given to 
immunomodulatory or anti-inflammatory properties. More clinical studies in humans that specifically 
investigate the effects of honey combination therapies for the treatment of wounds and skin lesions 
are needed. Future research may involve combining honey with other bioactive agents such as 
polyphenols, other plant derived compounds or other agents known to accelerate wound healing such 
as hyaluronic acid 62. Such novel approaches to treatment could be considered not only for wounds 
but also other types of skin disease. Honey is a relatively cheap substance that could be utilised 
globally as a combination therapy if efficacy is established.  Furthermore, the reduction or 
replacement of antibiotic use with other therapies has the potential to lower the risk of development 
of antibiotic resistant bacterial strains. Honey combination therapies have the potential to improve 
clinical outcomes for patients with wound and skin infections and therefore further research in this 
area should be encouraged.     
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